News & Events – Page 7 – Sumitovant

Select Company

October 17, 2019Female Forward Together, a Cross-Sector Coalition, Announced to Advance Research, Education, and Action for Women’s Health
October 10, 2019Myovant Sciences Announces Late-Breaking Oral Presentation of Phase 3 LIBERTY 1 & 2 Study Results at 2019 American Society for Reproductive Medicine Scientific Congress
September 06, 2019Myovant Sciences’ Founding Shareholder Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create a Broad Strategic Alliance
August 27, 2019Myovant Sciences to Participate in Upcoming September Investor Conferences
August 27, 2019CORRECTION: Myovant Sciences to Participate in Upcoming September Investor Conferences
August 20, 2019Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 2 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
August 06, 2019Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for First Fiscal Quarter Ended June 30, 2019
July 23, 2019Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and Positive Results from Bioequivalence Study
July 22, 2019Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, July 23rd to Discuss Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and from Bioequivalence Study
July 10, 2019Myovant Sciences and Evidation Health Announce Partnership and Launch Digital Insights Study on Menstruation
« Previous 1 … 5 6 7 8 Next »